Candel Therapeutics Statistics
Total Valuation
CADL has a market cap or net worth of $280.81 million. The enterprise value is $191.63 million.
Important Dates
The last earnings date was Thursday, March 13, 2025, after market close.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CADL has 47.24 million shares outstanding. The number of shares has increased by 9.47% in one year.
| Current Share Class | 47.24M |
| Shares Outstanding | 47.24M |
| Shares Change (YoY) | +9.47% |
| Shares Change (QoQ) | +11.09% |
| Owned by Insiders (%) | 8.98% |
| Owned by Institutions (%) | 40.80% |
| Float | 35.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.20 |
| P/TBV Ratio | 4.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.20.
| Current Ratio | 2.77 |
| Quick Ratio | 2.74 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.61 |
Financial Efficiency
Return on equity (ROE) is -139.56% and return on invested capital (ROIC) is -35.37%.
| Return on Equity (ROE) | -139.56% |
| Return on Assets (ROA) | -27.55% |
| Return on Invested Capital (ROIC) | -35.37% |
| Return on Capital Employed (ROCE) | -47.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +286.04% in the last 52 weeks. The beta is -1.28, so CADL's price volatility has been lower than the market average.
| Beta (5Y) | -1.28 |
| 52-Week Price Change | +286.04% |
| 50-Day Moving Average | 8.18 |
| 200-Day Moving Average | 6.73 |
| Relative Strength Index (RSI) | 32.03 |
| Average Volume (20 Days) | 1,052,800 |
Short Selling Information
The latest short interest is 3.45 million, so 7.31% of the outstanding shares have been sold short.
| Short Interest | 3.45M |
| Short Previous Month | 3.34M |
| Short % of Shares Out | 7.31% |
| Short % of Float | 9.61% |
| Short Ratio (days to cover) | 7.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | -18.23M |
| Operating Income | -32.63M |
| Pretax Income | -37.37M |
| Net Income | -55.18M |
| EBITDA | -31.64M |
| EBIT | -32.63M |
| Earnings Per Share (EPS) | -$1.74 |
Full Income StatementBalance Sheet
The company has $102.65 million in cash and $13.47 million in debt, giving a net cash position of $89.18 million or $1.89 per share.
| Cash & Cash Equivalents | 102.65M |
| Total Debt | 13.47M |
| Net Cash | 89.18M |
| Net Cash Per Share | $1.89 |
| Equity (Book Value) | 66.33M |
| Book Value Per Share | 1.42 |
| Working Capital | 66.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.02 million and capital expenditures -$16,000, giving a free cash flow of -$27.04 million.
| Operating Cash Flow | -27.02M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -27.04M |
| FCF Per Share | -$0.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |